# US 9,006,398 B2 · EPHB3-specific antibody and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,006,398 B2
- Document ID: US9006398B2
- Status: Granted
- Kind: B2
- Application number: 14/055,376
- Filed: 2013-10-16
- Published: 2014-05-29
- Granted: 2015-04-14
- Earliest claimed: 2006-08-04
- Assignees: Novartis AG; Xoma Technology Ltd.
- Applicants: Novartis AG; XOMA Technology Ltd.
- Inventors: Jeff Hsu; Linda Masat; Judy Abraham; Masahisa Handa; Siew Schleyer
- Web page: https://patentgrep.com/patent/US9006398B2

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.

## Claims

### Claim 1

The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Patent Deposit Designation PTA-7779.

### Claim 2

The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Patent Deposit Designation PTA-7786.

### Claim 3

The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Patent Deposit Designation PTA-7785.

### Claim 4

The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Patent Deposit Designation PTA-7782.

### Claim 5

The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Patent Deposit Designation PTA-7781.

### Claim 6

The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Patent Deposit Designation PTA-7780.

### Claim 7

The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Patent Deposit Designation PTA-7784.

### Claim 8

The monoclonal antibody produced by the hybridoma cell line deposited under American Type Culture Collection Patent Deposit Designation PTA-7783.